葆元

banner1
banner2
banner3
banner4
banner5
Previous
Next

Management

Junyuan Wang,
Ph.D.

Co-Founder
CEO

Readme

Bing Yan,
M.D., MBA

Co-Founder
Chief Medical Officer

Readme

Lihua Zheng,
J.D., Ph.D.

Co-Founder
Chief Business Officer

Readme

News

Chinese Center for Drug Evaluation (CDE) Cleared Taletrectinib IND and Issued Clinical Trial Authorizations for Two Phase 2 Clinical Trials in China
Research results of AnHeart’s new-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications
AnHeart Therapeutics Won the 2019 Sullivan China New Economy
AnHeart Therapeutics completed 100 million Chinese Yuan Series A round of financing; new anti-cancer drugs to enter China's clinical trials
Scroll to top